Elicio Therapeutics (ELTX) EPS (Weighted Average and Diluted) (2020 - 2026)
Elicio Therapeutics (ELTX) reported EPS (Weighted Average and Diluted) of -$0.65 for Q1 2026, up 25.29% on a YoY basis from -$0.52 in Q1 2025, and down 32.65% quarter-over-quarter from -$0.49 in Q4 2025.
Elicio Therapeutics (ELTX) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Elicio Therapeutics has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.65 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 25.29% year-over-year to -$0.65; the trailing twelve-month figure through Mar 2026 stood at -$2.4 (up 38.78% YoY), and the FY2025 full-year result was -$2.58, up 39.29% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.65, down from -$0.49 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.21 in Q4 2023, with the low at -$24.77 in Q1 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$6.08 across 5 years, with a median of -$1.02 in 2024.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 98.99% in 2023 against a maximum downside of 5060.42% in 2023.
- Elicio Therapeutics' EPS (Weighted Average and Diluted) stood at -$20.75 in 2022, then soared by 98.99% to -$0.21 in 2023, then tumbled by 385.71% to -$1.02 in 2024, then surged by 51.96% to -$0.49 in 2025, then tumbled by 32.65% to -$0.65 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.65 (Q1 2026), -$0.49 (Q4 2025), and -$0.6 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Elicio Therapeutics | 70.12 Mn | 55.17 Mn | - | -0.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.65 |
| Dec 31, 2025 | -0.49 |
| Sep 30, 2025 | -0.60 |
| Jun 30, 2025 | -0.66 |
| Mar 31, 2025 | -0.87 |
| Dec 31, 2024 | -1.02 |
| Sep 30, 2024 | -1.39 |
| Jun 30, 2024 | -0.64 |
| Mar 31, 2024 | -1.15 |
| Dec 31, 2023 | -0.21 |
| Sep 30, 2023 | -1.27 |
| Jun 30, 2023 | -2.61 |
| Mar 31, 2023 | -24.77 |
| Dec 31, 2022 | -20.75 |
| Sep 30, 2022 | -22.67 |
| Jun 30, 2022 | -23.20 |
| Mar 31, 2022 | -0.48 |
| Dec 31, 2021 | 0.58 |
| Sep 30, 2021 | -0.53 |
| Jun 30, 2021 | -0.58 |